Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started

Apogee Therapeutics, Inc.

2024-Q2 EPS reported -$1.24

Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.
Cash $789.6M as of June 30, 2024; runway into Q1 2028.
First patient dosed in APG777 Phase 2 trial; 16-week proof-of-concept data expected 2H2025.
APG808 interim Phase 1 data Q4 2024; APG990 Phase 1 trial accelerated to Q3 2024.
Added APG333 (anti-TSLP) to pipeline; entering clinic in 2025; combinations planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.